AAA produces nuclear pharmaceuticals including NETSPOT and Lutathera

Cancer immunotherapy is the use of the immune system to treat cancer. Immunotherapies can be categorized as active, passive or hybrid.  See Wikipedia

177Lutetium (177Lu) has gained popularity as the therapeutic radionuclide of choice due to its desirable physical properties. Ideally, the emission characteristics of a therapeutic radionuclide should match the lesion size/volume to be treated to ideally focus energy within the tumour rather than in the tissue surrounding the lesion.

Lutathera® (lutetium Lu 177 dotatate*) is for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors, in adults. 

Peptide Receptor Radionuclide Therapy (PRRT), a form of treatment comprising of a targeting molecule that carries a radioactive component

Professional Society of 15,000 members supporting nuclear imaging and therapies based in Reston, VA. SNMMI.ORG

is a treatment strategy that combines therapeutics with diagnostics. It associates both a diagnostic test that identifies patients most likely to be helped or harmed by a new medication, and targeted drug therapy based on the test results. Ga68 Dotatate (NETSPOT) and Lu177 Dotatate (Lutathera) are Theragnostic pairs.

telotristat ethyl controls diarrhea for those whose diarrhea is serotonin produced. telotristat ethyl method of action is to inhibit seroatonin production.